Maccura Biotechnology Co.Ltd (SHE:300463)
China · Delayed Price · Currency is CNY 10.32
+0.06 (0.58%)
May 19, 2026, 10:15 AM CST
SHE:300463 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,135 | 2,170 | 2,525 | 2,862 | 3,568 | 3,934 |
Other Revenue | - | - | 23.39 | 33.95 | 40.18 | 46.47 |
| 2,135 | 2,170 | 2,549 | 2,896 | 3,608 | 3,981 | |
Revenue Growth (YoY) | -12.58% | -14.84% | -11.98% | -19.75% | -9.35% | 7.47% |
Cost of Revenue | 870.75 | 890.54 | 1,173 | 1,384 | 1,712 | 1,740 |
Gross Profit | 1,265 | 1,280 | 1,376 | 1,512 | 1,897 | 2,240 |
Selling, General & Admin | 917.49 | 903.97 | 789.95 | 805.79 | 749.75 | 756.1 |
Research & Development | 327.03 | 317.94 | 323.15 | 324.17 | 273.22 | 207.27 |
Other Operating Expenses | 0.6 | 3.25 | 10.65 | 11.73 | 22.02 | 28.77 |
Operating Expenses | 1,245 | 1,225 | 1,114 | 1,180 | 1,081 | 999.91 |
Operating Income | 19.59 | 54.76 | 262.16 | 331.6 | 815.54 | 1,240 |
Interest Expense | -0.47 | - | -22.12 | -33.53 | -35.06 | -59.27 |
Interest & Investment Income | - | - | 9.33 | 18.62 | 24.15 | 5.4 |
Currency Exchange Gain (Loss) | - | - | 0.16 | 1.11 | 5.33 | -2.19 |
Other Non Operating Income (Expenses) | -101.87 | -100.54 | -1.41 | -2.38 | 3.2 | -3 |
EBT Excluding Unusual Items | -82.75 | -45.78 | 248.12 | 315.42 | 813.17 | 1,181 |
Impairment of Goodwill | - | - | -94.11 | - | - | - |
Gain (Loss) on Sale of Investments | -0.91 | -12.29 | 2.15 | -7.08 | -9.1 | - |
Gain (Loss) on Sale of Assets | 1.59 | -2.31 | -6.73 | -4.17 | -4.12 | -4.05 |
Asset Writedown | -38.5 | -39.16 | -36.54 | -9.54 | -22.46 | -26.01 |
Other Unusual Items | - | - | 11.77 | 10.73 | 11.59 | 35.81 |
Pretax Income | -120.57 | -99.54 | 124.65 | 305.37 | 789.08 | 1,187 |
Income Tax Expense | -60.23 | -58.04 | 5.89 | 0.69 | 87.38 | 184.88 |
Earnings From Continuing Operations | -60.34 | -41.49 | 118.76 | 304.68 | 701.71 | 1,002 |
Minority Interest in Earnings | 9.52 | 5.67 | 8.04 | 7.94 | 6.48 | -45.64 |
Net Income | -50.82 | -35.83 | 126.81 | 312.62 | 708.18 | 956.6 |
Net Income to Common | -50.82 | -35.83 | 126.81 | 312.62 | 708.18 | 956.6 |
Net Income Growth | - | - | -59.44% | -55.86% | -25.97% | 20.49% |
Shares Outstanding (Basic) | 602 | 604 | 606 | 609 | 604 | 553 |
Shares Outstanding (Diluted) | 602 | 604 | 613 | 612 | 608 | 557 |
Shares Change (YoY) | -1.70% | -1.38% | 0.01% | 0.77% | 9.16% | -0.11% |
EPS (Basic) | -0.08 | -0.06 | 0.21 | 0.51 | 1.17 | 1.73 |
EPS (Diluted) | -0.08 | -0.06 | 0.21 | 0.51 | 1.17 | 1.72 |
EPS Growth | - | - | -59.44% | -56.19% | -32.18% | 20.62% |
Free Cash Flow | -6.06 | -146.74 | -329.22 | 23.61 | -144.52 | 1,015 |
Free Cash Flow Per Share | -0.01 | -0.24 | -0.54 | 0.04 | -0.24 | 1.82 |
Dividend Per Share | - | - | 0.104 | 0.154 | 0.349 | 0.471 |
Dividend Growth | - | - | -32.48% | -55.89% | -25.86% | 9.30% |
Gross Margin | 59.22% | 58.97% | 53.99% | 52.20% | 52.57% | 56.28% |
Operating Margin | 0.92% | 2.52% | 10.29% | 11.45% | 22.60% | 31.16% |
Profit Margin | -2.38% | -1.65% | 4.98% | 10.80% | 19.63% | 24.03% |
Free Cash Flow Margin | -0.28% | -6.76% | -12.92% | 0.81% | -4.00% | 25.50% |
EBITDA | 386.14 | 411.97 | 582.02 | 626.55 | 1,068 | 1,463 |
EBITDA Margin | 18.08% | 18.98% | 22.84% | 21.64% | 29.60% | 36.75% |
D&A For EBITDA | 366.55 | 357.21 | 319.86 | 294.94 | 252.56 | 222.54 |
EBIT | 19.59 | 54.76 | 262.16 | 331.6 | 815.54 | 1,240 |
EBIT Margin | 0.92% | 2.52% | 10.29% | 11.45% | 22.60% | 31.16% |
Effective Tax Rate | - | - | 4.72% | 0.23% | 11.07% | 15.57% |
Revenue as Reported | - | - | 2,549 | 2,896 | 3,608 | 3,981 |
Advertising Expenses | - | - | 58.56 | 104.69 | 96.23 | 114.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.